FORTREA HOLDINGS INC. Selling, General and Administrative Expense
FORTREA HOLDINGS INC. (FTRE) reported Selling, General and Administrative Expense of $102.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-07-29
- FORTREA HOLDINGS INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $102.10M, a 18.19% decline year-over-year.
- FORTREA HOLDINGS INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $100.50M, a 17.49% decline year-over-year.
- FORTREA HOLDINGS INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $103.00M, a 30.45% decline year-over-year.
- FORTREA HOLDINGS INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $106.80M, a 21.64% decline year-over-year.
- FORTREA HOLDINGS INC. selling, general and administrative expense for fiscal 2025 was $456.40M, a 18.60% decline from fiscal 2024.
- FORTREA HOLDINGS INC. selling, general and administrative expense for fiscal 2024 was $560.70M, a 25.13% increase from fiscal 2023.
- FORTREA HOLDINGS INC. selling, general and administrative expense for fiscal 2023 was $448.10M, a 7.69% increase from fiscal 2022.
- FORTREA HOLDINGS INC. selling, general and administrative expense for fiscal 2022 was $416.10M, a 37.28% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $102.10M 10-Q · filed 2026-07-29 | $202.60M 10-Q · filed 2026-07-29 | $305.60M derived: sum of 3 quarters · filed 2026-07-29 | $412.40M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2026-03-31 | $100.50M 10-Q · filed 2026-05-05 | $203.50M derived: sum of 2 quarters · filed 2026-05-05 | $310.30M derived: sum of 3 quarters · filed 2026-05-05 | $435.10M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-12-31 | $103.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $209.80M derived: sum of 2 quarters · filed 2026-02-26 | $334.60M derived: sum of 3 quarters · filed 2026-07-29 | $456.40M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $106.80M 10-Q · filed 2025-11-05 | $231.60M derived: sum of 2 quarters · filed 2026-07-29 | $353.40M 10-Q · filed 2025-11-05 | $501.50M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-06-30 | $124.80M 10-Q · filed 2026-07-29 | $246.60M 10-Q · filed 2026-07-29 | $394.70M derived: sum of 3 quarters · filed 2026-07-29 | $531.00M derived: sum of 4 quarters · filed 2026-07-29 | ||||
| 2025-03-31 | $121.80M 10-Q · filed 2026-05-05 | $269.90M derived: sum of 2 quarters · filed 2026-05-05 | $406.20M derived: sum of 3 quarters · filed 2026-05-05 | $562.40M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $148.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $284.40M derived: sum of 2 quarters · filed 2026-02-26 | $440.60M derived: sum of 3 quarters · filed 2026-02-26 | $560.70M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $136.30M 10-Q · filed 2025-11-05 | $292.50M derived: sum of 2 quarters · filed 2025-11-05 | $412.60M 10-Q · filed 2025-11-05 | $539.30M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $156.20M 10-Q · filed 2025-08-06 | $276.30M 10-Q · filed 2025-08-06 | $403.00M derived: sum of 3 quarters · filed 2026-02-26 | $509.80M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $120.10M 10-Q · filed 2025-05-12 | $246.80M derived: sum of 2 quarters · filed 2026-02-26 | $353.60M derived: sum of 3 quarters · filed 2026-02-26 | $451.40M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $126.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $233.50M derived: sum of 2 quarters · filed 2026-02-26 | $331.30M derived: sum of 3 quarters · filed 2026-02-26 | $448.10M 10-K · filed 2026-02-26 | $336.60M 10-K · filed 2024-03-13 | |||
| 2023-09-30 | $106.80M 10-Q · filed 2024-11-08 | $78.90M 10-Q · filed 2023-11-13 | $204.60M derived: sum of 2 quarters · filed 2024-11-08 | $321.40M 10-Q · filed 2024-11-08 | $237.70M 10-Q · filed 2023-11-13 | $521.00M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-06-30 | $97.80M 10-Q · filed 2024-08-12 | $80.80M 10-Q · filed 2023-08-14 | $214.60M 10-Q · filed 2024-08-12 | $158.80M 10-Q · filed 2023-08-14 | $414.20M derived: sum of 3 quarters · filed 2025-03-03 | $484.90M derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-03-31 | $116.80M 10-Q · filed 2024-05-24 | $316.40M derived: sum of 2 quarters · filed 2025-03-03 | $387.10M derived: sum of 3 quarters · filed 2025-03-03 | $458.30M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2022-12-31 | $199.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $270.30M derived: sum of 2 quarters · filed 2025-03-03 | $341.50M derived: sum of 3 quarters · filed 2025-03-03 | $416.10M 10-K · filed 2025-03-03 | $279.80M 10-K · filed 2024-03-13 | |||
| 2022-09-30 | $70.70M 10-Q · filed 2023-11-13 | $141.90M derived: sum of 2 quarters · filed 2023-11-13 | $216.50M 10-Q · filed 2023-11-13 | |||||
| 2022-06-30 | $71.20M 10-Q · filed 2023-08-14 | $145.80M 10-Q · filed 2023-08-14 | ||||||
| 2021-12-31 | $303.10M 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |